Table 1.
Height loss > 5 cm (n=649) |
Height loss ≤ 5 cm (n=2,475) |
P value | |
---|---|---|---|
Characteristicsa | |||
Year 0 age (years), mean (SD) | 70.2 ± 3.8 | 68.8 ± 3.2 | <0.001 |
Year 15 age (years), mean (SD) | 85.3 ± 3.8 | 83.7 ± 3.3 | <0.001 |
Year 0 height (cm), mean (SD) | 160.0 ± 5.6 | 160.1 ± 5.8 | 0.82 |
Year 15 height (cm), mean (SD) | 153.0 ± 6.1 | 157.3 ± 5.9 | <0.001 |
Year 0 weight (kg), mean (SD) | 67.8 ± 11.9 | 68.1 ± 12.1 | 0.51 |
Year 15 weight (kg), mean (SD) | 61.3 ± 11.6 | 66.1 ± 12.5 | <0.001 |
Walking for exercise | 31.7% | 39.3% | <0.001 |
Self-reported health (excellent/good) | 71.0% | 77.7% | <0.001 |
Current smoker | 2.6% | 2.5% | 0.87 |
Year 0 prevalent vertebral fractureb | 23.8% | 12.7% | <0.0001 |
Year 15 incident vertebral fracturec | 42.3% | 12.3% | <0.001 |
Year 0 self-report of non-vertebral fracture after age 50 | 35.6% | 30.0% | 0.007 |
Year 0 BMD (g/cm2), mean (SD) | 0.75 ± 0.12 | 0.79 ± 0.12 | <0.001 |
Year 15 BMD (g/cm2), mean (SD) | 0.67 ± 0.14 | 0.74 ± 0.13 | <0.001 |
Height loss from age 25 to year 0, mean (SD)d | 3.4 ± 2.6 | 2.5 ± 2.4 | <0.0001 |
Height loss from year 0 to year 15, mean (SD) | 7.0 ± 2.1 | 2.8 ± 1.5 | <0.0001 |
Outcomes after year 15 height loss measured | |||
Hip fracture, n (%) | 76 (12.9%) | 148 (6.4%) | <0.0001 |
Non-spine fracture, n (%) | 193 (32.5%) | 468 (20.0%) | <0.0001 |
Mortality, n (%) | 302 (46.5%) | 707 (28.6%) | <0.0001 |
Atherosclerosis | 98 (22.0%) | 252 (12.5%) | <0.0001 |
Cancer | 32 (8.4%) | 131 (6.9%) | 0.29 |
Non-athero/non-cancer | 172 (33.1%) | 324 (15.5%) | <0.0001 |
“Year 0” SOF exam is when initial height measured, and some Year 0 exam characteristics are reported for reference. Unless specified otherwise, characteristics are measured at Year 15 exam (Year 15 is the “baseline” for this analysis as it’s both when final height measured and when follow-up for fractures and mortality began).
Year 0 prevalent morphometric vertebral fractures on spine x-ray
Year 15 vertebral fractures are incident morphometric vertebral fractures that developed on repeat spine x-ray over the same 15 year interval as the height loss
As for all of Table 1, these means are in the primary analysis cohort (n=3,124)